Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy




Brentuximab vedotin, Cost-analysis, Economic evaluation, Hodgkin lymphoma, Italy


Introduction: This study estimates the change in the costs of second-line or later (2L+) treatments compared to the current scenario, associated with the introduction of brentuximab vedotin (Adcetris®) (BV) in combination with doxorubicin, vinblastine and dacarbazine (A+AVD) for the treatment of previously untreated (1L) patients with stage IV classical Hodgkin’s lymphoma (cHL).

Methods: An economic model has been developed that estimates the variation in treatment costs of 2L+ associated with the introduction of BV in 1L from the point of view of the Italian National Health System over a time horizon of 3 years. The population eligible to receive a treatment of 2L+ has been estimated from the literature, considering an increasing consumption in the three years of A+AVD in 1L. Two main scenarios and several alternative scenarios were considered to address the uncertainty that characterizes the distribution of market shares of 2L+ treatments.

Results: In the baseline scenario, over three years, the introduction of BV in 1L is associated with a cumulative reduction in treatment costs of 2L+ of € 1.74 M. In all scenarios, a reduction in treatment costs of 2L+ is confirmed, with a total saving that varies between € 5.6 M and € 1.3 M compared to the main scenarios.

Conclusions: The present analysis shows that the introduction of A+AVD in 1L for the treatment of stage IV CD30+ cHL patients is associated with a reduction in treatment costs of 2L+, even if there are some limitations related to the uncertainty of real cost and population estimates.


Opinto G, Agostinelli C, Ciavarella S, Guarini A, Maiorano E, Ingravallo G. Hodgkin Lymphoma: A Special Microenvironment. J Clin Med. 2021;10(20):4665. PMID:34682791 DOI:

AIRTUM. I numeri del cancro in Italia 2020. 2020. Online (Accessed July 2022)

Luminari S, Cesaretti M, Rashid I, et al. Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. Hematol Oncol. 2007;25(4):189-197. PMID:17654762 DOI:

Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet. 2021;398(10310):1518-1527. PMID:33493434 DOI:

Associazione Italiana di Oncologia Medica (AIOM). Linee guida. Linfomi; 2018.

Gazzetta Ufficiale della Repubblica Italiana: Serie Generale n.223 del 17-09-2021. Online (Accessed July 2022)

7. Gazzetta Ufficiale della Repubblica Italiana. Online (Accessed July 2022)

8. European Medicines Agency (EMA): CHMP post-authorisation summary of positive opinion for Adcetris (II-70). 26 March 2020. Online (Accessed July 2022)

Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e410-e421. PMID:34048680 DOI:

Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821. PMID:21047225 DOI:

Connors JM, Jurczak W, Straus DJ, et al; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018;378(4):331-344. PMID:29224502 DOI:

Collins GP, Rueda A, Salles G, von Tresckow B, Zaja F. Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. Leuk Lymphoma. 2018;59(9):2113-2120. PMID:29334819 DOI:

Esquirol A, Pascual MJ, Garcia-Cadenas I, et al. Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021;27(7):614.e1-614.e8. PMID:33775908 DOI:

Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30(4):612-620. PMID:30657848 DOI:

Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183-1194. PMID:29229594 DOI:

Musso M, Scalone R, Marcacci G, et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant. 2010;45(7):1147-1153. PMID:19898504 DOI:

Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020;38(32):3794-3804. PMID:32701411 DOI:

Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35-41. PMID:17229633 DOI:

Santoro A, Mazza R, Pulsoni A, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020;4(1):136-140. PMID:31935284 DOI:

Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419-3425. PMID:21816830 DOI:

AIFA. Riassunto delle Caratteristiche del Prodotto. Adcetris. Online (Accessed July 2022)

AIFA. Riassunto delle Caratteristiche del Prodotto. Opdivo. Online (Accessed July 2022)

Riassunto delle Caratteristiche del Prodotto. Keytruda. Online (Accessed July 2022)

Gazzetta Ufficiale della Repubblica Italiana: GU Serie Generale n.23 del 28-01-2013 – Suppl. Ordinario n. 8 – Allegato I. Online (Accessed July 2022)

Gazzetta Ufficiale della Repubblica Italiana: GU Serie Generale n.23 del 28-01-2013. Online

Lucioni C, Iannazzo S, Mazzi S, Saporiti G, Chiroli S. Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy. Glob Reg Health Technol Assess. 2015;1:1-16. DOI:

ISTAT. Rivaluta. Online (Accessed August 2022)

Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy. 2006;77(1):51-63. PMID:16139925 DOI:

Palmieri V, Baldi C, Di Blasi PE, et al. Impact of DRG billing system on health budget consumption in percutaneous treatment of mitral valve regurgitation in heart failure. J Med Econ. 2015;18(2):89-95. PMID:25350644 DOI:

Filetti S, Ladenson PW, Biffoni M, D’Ambrosio MG, Giacomelli L, Lopatriello S. The true cost of thyroid surgery determined by a micro-costing approach. Endocrine. 2017;55(2):519-529. PMID:27172916 DOI:

Berto P, Lopatriello S, Aiello A, et al. Cost of laparoscopy and laparotomy in the surgical treatment of colorectal cancer. Surg Endosc. 2012;26(5):1444-1453. PMID:22179444 DOI:



How to Cite

Fiorentino F, Canali B, Morelli P, Demma F. Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy. AboutOpen [Internet]. 2023 Jan. 16 [cited 2023 Dec. 4];10(1):6-12. Available from:



Original research articles


Received 2022-08-29
Accepted 2022-12-07
Published 2023-01-16